-$0.14 EPS Expected for Genocea Biosciences Inc (GNCA) This Quarter

Brokerages predict that Genocea Biosciences Inc (NASDAQ:GNCA) will announce earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.15). Genocea Biosciences posted earnings per share of ($0.54) in the same quarter last year, which suggests a positive year over year growth rate of 74.1%. The business is expected to announce its next quarterly earnings results on Wednesday, August 8th.

On average, analysts expect that Genocea Biosciences will report full-year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.62). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14).



Several equities research analysts recently commented on GNCA shares. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Robert W. Baird started coverage on shares of Genocea Biosciences in a research report on Monday, February 12th. They issued an “outperform” rating and a $3.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Genocea Biosciences in a research report on Monday, March 5th. They issued an “overweight” rating and a $5.00 price objective on the stock. HC Wainwright set a $5.00 price objective on shares of Genocea Biosciences and gave the company a “buy” rating in a research report on Monday, April 30th. Finally, ValuEngine raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $4.41.

A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System increased its stake in Genocea Biosciences by 166.6% in the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 78,469 shares during the last quarter. GSA Capital Partners LLP increased its stake in Genocea Biosciences by 266.9% in the 1st quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 170,265 shares during the last quarter. NEA Management Company LLC acquired a new stake in Genocea Biosciences in the 1st quarter valued at $26,250,000. BlackRock Inc. increased its stake in Genocea Biosciences by 169.1% in the 1st quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after buying an additional 2,488,540 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Genocea Biosciences by 164.5% in the 1st quarter. Northern Trust Corp now owns 792,677 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 492,961 shares during the last quarter. Hedge funds and other institutional investors own 61.94% of the company’s stock.

GNCA traded down $0.02 during trading on Friday, hitting $0.91. The company had a trading volume of 384,538 shares, compared to its average volume of 467,098. The stock has a market capitalization of $80.76 million, a P/E ratio of -0.46 and a beta of 1.20. Genocea Biosciences has a one year low of $0.79 and a one year high of $6.78. The company has a current ratio of 8.06, a quick ratio of 8.06 and a debt-to-equity ratio of 1.00.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply